Strategic research in life sciences and biotechnology

[searchwp_form id="3"]

Crispr‑enhanced T Cell Therapies

1 May, 2024 – 1 May, 2025

Utilizing CRISPR/Cas9, we edit T cells to boost tumor‑homing receptors and resist inhibitory signals within the tumor microenvironment. Preclinical safety and persistence studies will inform protocol optimization. This translational pipeline aims to advance lead candidates into first‑in‑human trials.

Reprogramming patient immune cells for precision cancer immunotherapy.

Team Heading Goes Here

Team description goes here

News Heading Goes Here

Research Labs Heading Goes Here

Our labs bring together multidisciplinary teams at the forefront of biotechnology, each tackling a unique aspect of life‑science innovation. From engineering precision therapies and modeling human organs-on-chip to decoding cellular networks and harnessing sustainable bio‑processes, they seamlessly integrate cutting‑edge tools with translational focus. Together, they drive discovery, accelerate breakthroughs, and turn bold ideas into real‑world solutions that improve health and industry.

an accent heading for publications

Publications Heading Goes Here

Publications description goes here

  • 15-03-2017

    A Crispr-cas-based Recombinase Polymerase Amplification Assay for Ultra-sensitive Detection of Active Trypanosoma Brucei Evansi Infections.

    Abstract Crispr

    Incididunt et sed do ipsum amet ipsum . consectetur amet dolor aliqua. ut adipiscing . amet labore dolor ipsum . do incididunt tempor tempor sit ipsum aliqua. . elit consectetur Lorem amet amet dolor incididunt .

    sed dolore aliqua. dolore sed sed . sed consectetur ut do . sed labore dolore dolor . labore adipiscing Lorem aliqua. amet Lorem magna . magna sed eiusmod magna adipiscing dolore .

    consectetur et Lorem dolor dolore . consectetur incididunt tempor adipiscing labore adipiscing labore sed . ipsum sit adipiscing adipiscing magna dolor adipiscing . magna Lorem dolor incididunt consectetur (...)

  • 18-03-2010

    Impact of Elevation of Total Bilirubin Level and Etiology of the Liver Disease on Serum N-glycosylation Patterns in Mice and Humans

    The GlycoFibroTest and GlycoCirrhoTest are noninvasive alternatives for liver biopsy that can be used as a follow-up tool for fibrosis patients and to diagnose cirrhotic patients, respectively. These tests are based on the altered N-glycosylation of total serum protein. Our aim was to investigate the impact of etiology on the alteration of N-glycosylation and whether other characteristics of liver patients could have an influence on N-glycosylation. In human liver patients, no specific alteration could be found to make a distinction according to etiological factor, although alcoholic patients had a significant higher mean value for the GlycoCirrhoTest. Undergalactosylation did (...)

Job Heading Goes Here

Related Project Heading Goes Here

Related project accent heading goes here

Related project descriptiongoes here

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.